Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS.
Rocque GB, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, Jepsen E, Gauthier E, Wang Y, Montelongo MZ, Cappelleri JC, Karuturi MS, Tripathy D. Rocque GB, et al. Among authors: karuturi ms. Breast Cancer Res Treat. 2024 Nov 25. doi: 10.1007/s10549-024-07524-2. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39581892
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib.
Samjoo IA, Hall A, Chen C, Nguyen BN, Bartlett M, Smith ML, Harbeck N, Cappelleri JC, Karuturi M, Makari D, Arruda LS, Sandin R, Hanson K, Doan J. Samjoo IA, et al. Among authors: karuturi m. J Comp Eff Res. 2024 Oct;13(10):e240111. doi: 10.57264/cer-2024-0111. Epub 2024 Sep 10. J Comp Eff Res. 2024. PMID: 39254990 Free PMC article.
Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study.
Blum JL, DiCristo C, Gordon D, Karuturi MS, Oubre D, Jepsen E, Cuevas J, Lakhanpal S, Montelongo MZ, Zhang Z, Cappelleri JC, Wang Y, Tripathy D. Blum JL, et al. Among authors: karuturi ms. Breast Cancer Res Treat. 2024 Feb;203(3):463-475. doi: 10.1007/s10549-023-07145-1. Epub 2023 Oct 30. Breast Cancer Res Treat. 2024. PMID: 37903899 Free PMC article.
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
Ring A, Karuturi M, Smyth EN, Lokhandwala T, Sheffield KM, Willey J, Lunacsek O, Sapunar F, Cui ZL, Coutinho AD, Rybowski S. Ring A, et al. Among authors: karuturi m. Drugs Real World Outcomes. 2023 Dec;10(4):589-603. doi: 10.1007/s40801-023-00391-1. Epub 2023 Sep 29. Drugs Real World Outcomes. 2023. PMID: 37775689 Free PMC article.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. Yam C, et al. Among authors: karuturi m. Breast Cancer Res Treat. 2023 Jun;199(3):457-469. doi: 10.1007/s10549-023-06929-9. Epub 2023 Apr 15. Breast Cancer Res Treat. 2023. PMID: 37061619 Clinical Trial.
59 results